Coronavirus treatment hopes boost European stocks at open


For a live blog on European stocks, type LIVE/ in an Eikon news window

Aug 24 (Reuters) - European stocks bounced from a two-week low on Monday as signs of progress in developing a COVID-19 treatment offset fears about a resurgence in virus cases across the continent that could risk stifling an economic recovery.

The pan-European STOXX 600 index .STOXX rose 1.3% by 0713 GMT, mirroring gains for Asian markets after the U.S. health regulator said on Sunday it authorized the use of blood plasma from patients who have recovered from COVID-19 as a treatment.

Technology .SX8P, mining .SXPP and chemical .SX4P companies led the surge in early European trading, gaining more than 1.5%.

AstraZeneca Plc AZN.L was up 2.1% after the Financial Times reported the Trump administration was considering fast-tracking an experimental COVID-19 vaccine being developed by the company.

The gains come after a lacklustre week for European equities, which were pressured by data pointing to a stalling business recovery in the euro zone amid a surge in coronavirus cases.

British telecoms company BT Group BT.L jumped 6.1% to the top of STOXX 600 after a media report that its board was preparing to defend it against takeover approaches from rivals and buyout firms.

(Reporting by Sruthi Shankar in Bengaluru; Editing by Anil D'Silva)

((; within U.S. +1 646 223 8780; outside U.S. +91 80 6182 2787;))

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


More Related Articles

Info icon

This data feed is not available at this time.

Sign up for Smart Investing to get the latest news, strategies and tips to help you invest smarter.